JP2004525892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525892A5 JP2004525892A5 JP2002563137A JP2002563137A JP2004525892A5 JP 2004525892 A5 JP2004525892 A5 JP 2004525892A5 JP 2002563137 A JP2002563137 A JP 2002563137A JP 2002563137 A JP2002563137 A JP 2002563137A JP 2004525892 A5 JP2004525892 A5 JP 2004525892A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- trifluoromethyl
- bis
- formula
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 22
- -1 NH-phenyl Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000002757 morpholinyl group Chemical group 0.000 claims 8
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 claims 2
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 claims 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- GJMIULBZYICSMI-SFTDATJTSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-chlorophenyl)piperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C(F)(F)F)=O)C2=CC=C(C=C2)Cl)C=C(C1)C(F)(F)F)(F)F GJMIULBZYICSMI-SFTDATJTSA-N 0.000 claims 1
- CGARRQSZKTWYFN-NSOVKSMOSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-2-phenylethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(CC2=CC=CC=C2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F CGARRQSZKTWYFN-NSOVKSMOSA-N 0.000 claims 1
- GJMIULBZYICSMI-UHFFFAOYSA-N 1-[4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-chlorophenyl)piperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCN1C1C(C=2C=CC(Cl)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 GJMIULBZYICSMI-UHFFFAOYSA-N 0.000 claims 1
- VURZIUHIBJZQJU-ZEQRLZLVSA-N 2-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-N,N-dimethylacetamide Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)N(C)C)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F VURZIUHIBJZQJU-ZEQRLZLVSA-N 0.000 claims 1
- XILVWQMCIFIHBH-VMPREFPWSA-N 2-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=C(C=CC=C2C)C)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F XILVWQMCIFIHBH-VMPREFPWSA-N 0.000 claims 1
- XFCPGAHDBKKEEC-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-(4-methylphenyl)piperidine-1-carbaldehyde Chemical compound C1=CC(C)=CC=C1C1C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)(N2CCN(CC3CC3)CC2)CCN(C=O)C1 XFCPGAHDBKKEEC-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- PFQVGWLVKBANFL-SFTDATJTSA-N FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CC(CC2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CC(CC2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F PFQVGWLVKBANFL-SFTDATJTSA-N 0.000 claims 1
- FMVSQTXHPKIBOG-NSOVKSMOSA-N FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=CC=C(C=C2)F)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=CC=C(C=C2)F)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F FMVSQTXHPKIBOG-NSOVKSMOSA-N 0.000 claims 1
- RGVRXDVQDCRDNG-SFTDATJTSA-N FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCS(CC1)=O)C1=CC=CC=C1)(F)F Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCS(CC1)=O)C1=CC=CC=C1)(F)F RGVRXDVQDCRDNG-SFTDATJTSA-N 0.000 claims 1
- RSCZASMERGDWQG-NSOVKSMOSA-N [(3R,4S)-4-(4-benzylpiperazin-1-yl)-3-phenylpiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound C(C1=CC=CC=C1)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=CC=C1 RSCZASMERGDWQG-NSOVKSMOSA-N 0.000 claims 1
- CCXDRJAINCWDAQ-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=C(C=C1)Cl)(F)F CCXDRJAINCWDAQ-SFTDATJTSA-N 0.000 claims 1
- QDZJLISLPHCAPG-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC=C(C=C1)Cl)(F)F QDZJLISLPHCAPG-PKTZIBPZSA-N 0.000 claims 1
- NTDHCKSZBFQTJJ-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=CC=C(C=C1)F)(F)F NTDHCKSZBFQTJJ-VXKWHMMOSA-N 0.000 claims 1
- OJCHNZGIVNTAKX-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=C(C=C1)F)(F)F OJCHNZGIVNTAKX-SFTDATJTSA-N 0.000 claims 1
- MPHLYYLVNQTJED-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-piperazin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=C(C=C1)F)(F)F MPHLYYLVNQTJED-SFTDATJTSA-N 0.000 claims 1
- PSRRKURJBFCJJI-ZEQRLZLVSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(4-pyrazin-2-ylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C=2N=CC=NC=2)C=2C=CC=CC=2)=C1 PSRRKURJBFCJJI-ZEQRLZLVSA-N 0.000 claims 1
- PFNJHPGSNGDBSO-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-piperazin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=CC=C1)(F)F PFNJHPGSNGDBSO-SFTDATJTSA-N 0.000 claims 1
- BRJRXLQWTMSQBS-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-thiomorpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCSCC1)C1=CC=CC=C1)(F)F BRJRXLQWTMSQBS-SFTDATJTSA-N 0.000 claims 1
- UDRBQEGZZSNZJV-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(3-bromophenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)Br)C1=CC=CC=C1)(F)F UDRBQEGZZSNZJV-PKTZIBPZSA-N 0.000 claims 1
- QOPIJTBAENVABP-ZEQRLZLVSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-cyclopropylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C1CC1)C1=CC=CC=C1)(F)F QOPIJTBAENVABP-ZEQRLZLVSA-N 0.000 claims 1
- SVAYRKLDOZPACO-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=CC=CC=C1)(F)F SVAYRKLDOZPACO-VXKWHMMOSA-N 0.000 claims 1
- VWNSKHONTPQIBQ-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-morpholin-4-ylphenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)N1CCOCC1)C1=CC=CC=C1)(F)F VWNSKHONTPQIBQ-SXOMAYOGSA-N 0.000 claims 1
- VXKCYYXJWDLBCZ-FTJBHMTQSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(2-methoxyethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)NCCOC)C1=CC=CC=C1)(F)F VXKCYYXJWDLBCZ-FTJBHMTQSA-N 0.000 claims 1
- JYFFYYUGBWGEKI-IZLXSDGUSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(4-methylpiperazin-1-yl)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)N1CCN(CC1)C)C1=CC=CC=C1)(F)F JYFFYYUGBWGEKI-IZLXSDGUSA-N 0.000 claims 1
- RFBURTLUSXOIHK-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-(4-fluorophenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)CC1CC1)C1=CC=C(C=C1)F)(F)F RFBURTLUSXOIHK-DQEYMECFSA-N 0.000 claims 1
- HDGHBMSKSIBEPD-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)CC1CC1)C1=CC=CC=C1)(F)F HDGHBMSKSIBEPD-DQEYMECFSA-N 0.000 claims 1
- JEIFPGIGTTZXDQ-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(morpholine-4-carbonyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(=O)N2CCOCC2)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F JEIFPGIGTTZXDQ-DQEYMECFSA-N 0.000 claims 1
- IXPJTNGFNRDHMI-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-morpholin-4-yl-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=CC=C1)(F)F IXPJTNGFNRDHMI-SFTDATJTSA-N 0.000 claims 1
- XRUKHJOJTLIFMF-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-[4-(cyclopropylmethyl)piperazin-1-yl]piperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC3CC3)CC2)C=2C=CC(Cl)=CC=2)=C1 XRUKHJOJTLIFMF-UHFFFAOYSA-N 0.000 claims 1
- MMWYCGIIXQMACZ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-pyrrolidin-1-ylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCCC2)C=2C=CC(Cl)=CC=2)=C1 MMWYCGIIXQMACZ-UHFFFAOYSA-N 0.000 claims 1
- NTDHCKSZBFQTJJ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC(F)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 NTDHCKSZBFQTJJ-UHFFFAOYSA-N 0.000 claims 1
- IMBFYCYNNWNYJR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC(C)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 IMBFYCYNNWNYJR-UHFFFAOYSA-N 0.000 claims 1
- VWNHFOMGPDXVQE-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-[4-(morpholine-4-carbonyl)piperazin-1-yl]piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C(=O)N2CCOCC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 VWNHFOMGPDXVQE-UHFFFAOYSA-N 0.000 claims 1
- QOPIJTBAENVABP-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-(4-cyclopropylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C2CC2)C=2C=CC=CC=2)=C1 QOPIJTBAENVABP-UHFFFAOYSA-N 0.000 claims 1
- SVAYRKLDOZPACO-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 SVAYRKLDOZPACO-UHFFFAOYSA-N 0.000 claims 1
- ZWZOUGJACPPJBQ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound C1CN(CCO)CCN1C1C(C=2C=CC=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 ZWZOUGJACPPJBQ-UHFFFAOYSA-N 0.000 claims 1
- HDGHBMSKSIBEPD-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC3CC3)CC2)C=2C=CC=CC=2)=C1 HDGHBMSKSIBEPD-UHFFFAOYSA-N 0.000 claims 1
- UQABNGOOEFUUOI-ZEQRLZLVSA-N [4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C(=O)C1CC1)C1=CC=CC=C1)(F)F UQABNGOOEFUUOI-ZEQRLZLVSA-N 0.000 claims 1
- IKDCKWKTTNIJRM-UHFFFAOYSA-N [4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-methylphenyl)piperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C(=O)C2CC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 IKDCKWKTTNIJRM-UHFFFAOYSA-N 0.000 claims 1
- UQABNGOOEFUUOI-UHFFFAOYSA-N [4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C(=O)C2CC2)C=2C=CC=CC=2)=C1 UQABNGOOEFUUOI-UHFFFAOYSA-N 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 238000005576 amination reaction Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000006264 debenzylation reaction Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01102557 | 2001-02-06 | ||
| PCT/EP2002/000851 WO2002062784A1 (en) | 2001-02-06 | 2002-01-28 | Piperidinee derivatives as neurokinin 1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525892A JP2004525892A (ja) | 2004-08-26 |
| JP2004525892A5 true JP2004525892A5 (https=) | 2005-06-09 |
| JP4181409B2 JP4181409B2 (ja) | 2008-11-12 |
Family
ID=8176398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563137A Expired - Fee Related JP4181409B2 (ja) | 2001-02-06 | 2002-01-28 | ニューロキニン１アンタゴニストとしてのピペリジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6642226B2 (https=) |
| EP (1) | EP1360184B1 (https=) |
| JP (1) | JP4181409B2 (https=) |
| KR (1) | KR100566470B1 (https=) |
| CN (1) | CN1229373C (https=) |
| AR (1) | AR035427A1 (https=) |
| AT (1) | ATE292128T1 (https=) |
| AU (1) | AU2002228072B2 (https=) |
| BR (1) | BR0206915A (https=) |
| CA (1) | CA2435946C (https=) |
| DE (1) | DE60203481T2 (https=) |
| DK (1) | DK1360184T3 (https=) |
| ES (1) | ES2238560T3 (https=) |
| MX (1) | MXPA03006991A (https=) |
| PT (1) | PT1360184E (https=) |
| WO (1) | WO2002062784A1 (https=) |
| ZA (1) | ZA200305887B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81918C2 (uk) * | 2002-10-08 | 2008-02-25 | Янссен Фармацевтика Н.В. | Заміщені похідні 1,4-дипіперидин-4-ілпіперазину та їх застосування як нейрокінінових антагоністів |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| WO2004056805A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
| JO2696B1 (en) * | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
| JO2485B1 (en) | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
| BRPI0411290A (pt) | 2003-06-10 | 2006-08-29 | Janssen Pharmaceutica Nv | formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina |
| JO2525B1 (en) * | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin |
| US7880002B2 (en) * | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US7635698B2 (en) * | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| MX2007009949A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3. |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| ATE478075T1 (de) * | 2005-03-08 | 2010-09-15 | Janssen Pharmaceutica Nv | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten |
| KR101336106B1 (ko) | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| HRP20170621T1 (hr) | 2006-12-14 | 2017-07-28 | Janssen Pharmaceutica N.V. | Postupak za pripremanje derivata piperazinil i diazepanil benzamida |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| US8063075B2 (en) * | 2008-06-10 | 2011-11-22 | Hoffmann-La Roche Inc. | Pyrrolidine ether derivatives as NK3 receptor antagonists |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH545288A (de) | 1966-08-18 | 1974-01-31 | Sandoz Ag | Verfahren zur Herstellung neuer Piperidon-Derivate |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| CA2178219C (en) | 1993-12-29 | 2005-03-22 | Raymond Baker | Substituted morpholine derivatives and their use as therapeutic agents |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| GB9600235D0 (en) | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
| US6291496B1 (en) | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
-
2002
- 2002-01-25 US US10/057,450 patent/US6642226B2/en not_active Expired - Fee Related
- 2002-01-28 CN CNB028046064A patent/CN1229373C/zh not_active Expired - Fee Related
- 2002-01-28 ES ES02710043T patent/ES2238560T3/es not_active Expired - Lifetime
- 2002-01-28 DK DK02710043T patent/DK1360184T3/da active
- 2002-01-28 WO PCT/EP2002/000851 patent/WO2002062784A1/en not_active Ceased
- 2002-01-28 DE DE60203481T patent/DE60203481T2/de not_active Expired - Lifetime
- 2002-01-28 KR KR1020037010336A patent/KR100566470B1/ko not_active Expired - Fee Related
- 2002-01-28 EP EP02710043A patent/EP1360184B1/en not_active Expired - Lifetime
- 2002-01-28 AT AT02710043T patent/ATE292128T1/de not_active IP Right Cessation
- 2002-01-28 PT PT02710043T patent/PT1360184E/pt unknown
- 2002-01-28 AU AU2002228072A patent/AU2002228072B2/en not_active Ceased
- 2002-01-28 BR BR0206915-6A patent/BR0206915A/pt not_active IP Right Cessation
- 2002-01-28 CA CA002435946A patent/CA2435946C/en not_active Expired - Fee Related
- 2002-01-28 MX MXPA03006991A patent/MXPA03006991A/es active IP Right Grant
- 2002-01-28 JP JP2002563137A patent/JP4181409B2/ja not_active Expired - Fee Related
- 2002-02-01 AR ARP020100349A patent/AR035427A1/es unknown
-
2003
- 2003-07-30 ZA ZA2003/05887A patent/ZA200305887B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525892A5 (https=) | ||
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2003136097A (ru) | Производные фенилпиридинкарбонилпиперазина | |
| JP2004534010A5 (https=) | ||
| RU2007118538A (ru) | Производные хинолина | |
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| JP2008517926A5 (https=) | ||
| JP4181409B2 (ja) | ニューロキニン１アンタゴニストとしてのピペリジン誘導体 | |
| JP2011515462A5 (https=) | ||
| JP2006522771A5 (https=) | ||
| RU2000129161A (ru) | Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт | |
| RU2005114489A (ru) | N-акрил-4-метиленамино-3-гидрокси-2-пиридоны в качестве противомикробных препаратов | |
| JP2002533326A5 (https=) | ||
| JP2005533803A5 (https=) | ||
| JP2006504761A5 (https=) | ||
| CA2413086A1 (en) | Benzothiazole derivatives | |
| JP2002535323A5 (https=) | ||
| JP2006505590A5 (https=) | ||
| JP2006501306A5 (https=) | ||
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| RU2010108687A (ru) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 | |
| JPWO2021170109A5 (https=) |